Holen Sie sich die Stockscreener-App
36.34
5.73%
1.97
Handel nachbörslich:
36.34
Schlusskurs vom Vortag:
$34.37
Offen:
$35.01
24-Stunden-Volumen:
1.25M
Relative Volume:
1.02
Marktkapitalisierung:
$3.80B
Einnahmen:
$7.70M
Nettoeinkommen (Verlust:
$-465.32M
KGV:
-7.3494
EPS:
-4.9446
Netto-Cashflow:
$-383.68M
1W Leistung:
+0.80%
1M Leistung:
-16.25%
6M Leistung:
+1.25%
1J Leistung:
+3.62%
1-Tages-Spanne:
$34.89
$36.51
1-Wochen-Bereich:
$33.40
$36.51
52-Wochen-Spanne:
$24.10
$57.99
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Compare CRNX vs VRTX, REGN, ALNY, ARGX, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
36.34 | 3.60B | 7.70M | -465.32M | -383.68M | -4.9446 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-12 | Hochstufung | Goldman | Neutral → Buy |
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B (XLV:NYSEARCA) - Seeking Alpha
Crinetics Pharmaceuticals (CRNX) Executive Resignation Announced - GuruFocus
Crinetics Pharma COO to step down - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 4.3%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. Announces Resignation of Jeff Knight as Chief Development and Operating Officer, Effective on or About April 10, 2026 - marketscreener.com
Crinetics Pharmaceuticals, Inc. Files Form 8-K with SEC: Company Details, Stock Info, and Compliance Data (March 2026) - Minichart
Crinetics Pharmaceuticals chief development and operating officer to resign - Investing.com
Crinetics' Jeff Knight to Resign as Chief Development and Operating Officer - TradingView
Crinetics (NASDAQ: CRNX) COO-level executive Jeff Knight to resign by April 10, 2026 - Stock Titan
Q4 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q1 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Q3 2025 Crinetics Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Stock Market Recap: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsTake Profit & Daily Stock Trend Watchlist - baoquankhu1.vn
Merger Talk: Whats the beta of Crinetics Pharmaceuticals Inc stockWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
JPMorgan Chase & Co. Acquires 926,765 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
CRNX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Patterns Watch: What is the dividend yield of Crinetics Pharmaceuticals Inc2026 Retail & Weekly Top Gainers Alerts - baoquankhu1.vn
Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Stephen Betz Sells 10,612 Shares - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) CEO Sells $821,429.97 in Stock - MarketBeat
Crinetics Pharmaceuticals Insider Sold Shares Worth $821,513, According to a Recent SEC Filing - marketscreener.com
Crinetics Pharmaceuticals (CRNX) COO sells 9,911 shares for RSU taxes - Stock Titan
Crinetics (NASDAQ: CRNX) CSO sells shares to cover RSU tax - Stock Titan
Crinetics (CRNX) CEO discloses tax-related share sales under 10b5-1 plan - Stock Titan
CRNX (NASDAQ: CRNX) insider sells shares via 10b5-1 and option exercise - Stock Titan
Jim Cramer on Crinetics: “That’s a better spec than Aquestive” - MSN
CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill
[144] Crinetics Pharmaceuticals, Inc. SEC Filing - Stock Titan
First Light Asset Management LLC Acquires 77,380 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals announces $350M proposed public offering - MSN
Farallon Capital Management LLC Increases Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Checkpoint Capital L.P. Purchases Shares of 260,000 Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals (CRNX) Price Weakness Creating A Fresh Valuation Opportunity Now? - simplywall.st
Prosight Management LP Buys 30,561 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Is Crinetics Pharmaceuticals (CRNX) Pricing Reflect Its Sharp Swings And DCF Upside Potential - Yahoo Finance
Coelho Rogerio Vivaldi Sells 5,000 Shares of Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock - MarketBeat
Insider Sell: Coelho Vivaldi Sells 5,000 Shares of Crinetics Pha - GuruFocus
Crinetics Pharmaceuticals (CRNX) director sells 5,000 shares in planned trade - Stock Titan
Pier Capital LLC Has $3.12 Million Stake in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Assessing Crinetics Pharmaceuticals (CRNX) Valuation After Recent Share Price Volatility - Sahm
Crinetics Advances Atumelnant: Phase 1 Study Completion Sets Up Next Clinical Catalyst for CRNX - The Globe and Mail
Income Plays: Can Crinetics Pharmaceuticals Inc stock outperform in a bear market2026 Rallies & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Systematic review on acromegaly therapies receives journal approval, Crinetics Pharmaceuticals announces - Traders Union
(CRNX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
WINTON GROUP Ltd Takes Position in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Levels Update: Is Crinetics Pharmaceuticals Inc a stock for growth or value investorsMarket Activity Recap & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Rafferty Asset Management LLC Decreases Stock Holdings in Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat
Crinetics Pharmaceuticals Highlights Early PALSONIFY Sales, EU Milestone, and GPCR Pipeline at TD Cowen Conf. - Yahoo Finance
Should value investors consider Crinetics Pharmaceuticals Inc2026 Year in Review & Verified Momentum Stock Ideas - baoquankhu1.vn
Will Crinetics Pharmaceuticals Inc. stock attract more institutional investorsInsider Buying & High Win Rate Trade Alerts - Naître et grandir
Crinetics Pharmaceuticals, Inc. (CRNX)’ Oral Acromegaly Drug Nears FDA Decision After Strong Phase 3 Data - MSN
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):